Literature DB >> 29608318

Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Jaydeep Yadav1, Ken Korzekwa1, Swati Nagar1.   

Abstract

Time-dependent inactivation (TDI) of cytochrome P450s (CYPs) is a leading cause of clinical drug-drug interactions (DDIs). Current methods tend to overpredict DDIs. In this study, a numerical approach was used to model complex CYP3A TDI in human-liver microsomes. The inhibitors evaluated included troleandomycin (TAO), erythromycin (ERY), verapamil (VER), and diltiazem (DTZ) along with the primary metabolites N-demethyl erythromycin (NDE), norverapamil (NV), and N-desmethyl diltiazem (NDD). The complexities incorporated into the models included multiple-binding kinetics, quasi-irreversible inactivation, sequential metabolism, inhibitor depletion, and membrane partitioning. The resulting inactivation parameters were incorporated into static in vitro-in vivo correlation (IVIVC) models to predict clinical DDIs. For 77 clinically observed DDIs, with a hepatic-CYP3A-synthesis-rate constant of 0.000 146 min-1, the average fold difference between the observed and predicted DDIs was 3.17 for the standard replot method and 1.45 for the numerical method. Similar results were obtained using a synthesis-rate constant of 0.000 32 min-1. These results suggest that numerical methods can successfully model complex in vitro TDI kinetics and that the resulting DDI predictions are more accurate than those obtained with the standard replot approach.

Entities:  

Keywords:  drug−drug interactions; enzyme kinetic models; numerical method; time-dependent inhibition

Mesh:

Substances:

Year:  2018        PMID: 29608318      PMCID: PMC5938745          DOI: 10.1021/acs.molpharmaceut.8b00129

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  122 in total

1.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

2.  The pharmacological and pharmacokinetic properties of troleandomycin.

Authors:  E Genazzani
Journal:  Quad Antibiot       Date:  1975-06

3.  Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.

Authors:  Akiko Watanabe; Koichi Nakamura; Noriko Okudaira; Osamu Okazaki; Ken-ichi Sudo
Journal:  Drug Metab Dispos       Date:  2007-03-28       Impact factor: 3.922

Review 4.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

5.  Numerical analysis of time dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting.

Authors:  Chuong Pham; Swati Nagar; Ken Korzekwa
Journal:  Xenobiotica       Date:  2017-06-23       Impact factor: 1.908

6.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes.

Authors:  R W Wang; P H Kari; A Y Lu; P E Thomas; F P Guengerich; K P Vyas
Journal:  Arch Biochem Biophys       Date:  1991-11-01       Impact factor: 4.013

7.  The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

Authors:  R G McAllister; E B Kirsten
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

8.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.

Authors:  R A Stearns; P K Chakravarty; R Chen; S H Chiu
Journal:  Drug Metab Dispos       Date:  1995-02       Impact factor: 3.922

Review 9.  Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.

Authors:  Shu-Feng Zhou; Charlie Changli Xue; Xue-Qing Yu; Chunguang Li; Guangji Wang
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

10.  Metabolite inhibition of parent drug biotransformation. Studies of diltiazem.

Authors:  S C Tsao; T H Dickinson; D R Abernethy
Journal:  Drug Metab Dispos       Date:  1990 Mar-Apr       Impact factor: 3.922

View more
  10 in total

1.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

2.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

3.  Numerical Analysis of Time-Dependent Inhibition by MDMA.

Authors:  John T Rodgers; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2019-10-22       Impact factor: 3.922

4.  Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2019-05-01       Impact factor: 3.922

Review 5.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

6.  Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde.

Authors:  Michael J Espiritu; Justin Chen; Jaydeep Yadav; Michael Larkin; Robert D Pelletier; Jeannine M Chan; Jeevan B Gc; Senthil Natesan; John P Harrelson
Journal:  Drug Metab Dispos       Date:  2020-08-12       Impact factor: 3.922

7.  Using partition analysis as a facile method to derive net clearances.

Authors:  Ken Korzekwa; Jaydeep Yadav; Swati Nagar
Journal:  Clin Transl Sci       Date:  2022-06-02       Impact factor: 4.438

Review 8.  The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

Authors:  Nancy H C Loos; Jos H Beijnen; Alfred H Schinkel
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

9.  Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker.

Authors:  Miao Zhang; Zhiheng Yu; Xueting Yao; Zihan Lei; Kaijing Zhao; Wenqian Wang; Xue Zhang; Xijing Chen; Dongyang Liu
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

10.  Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.

Authors:  Rakshit S Tanna; Dan-Dan Tian; Nadja B Cech; Nicholas H Oberlies; Allan E Rettie; Kenneth E Thummel; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2020-10-22       Impact factor: 4.030

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.